129 related articles for article (PubMed ID: 35402570)
1.
Asano T; Chelvanambi S; Decano JL; Whelan MC; Aikawa E; Aikawa M
Front Cardiovasc Med; 2022; 9():842641. PubMed ID: 35402570
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
3. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
4. L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies.
Sendama W
Comput Struct Biotechnol J; 2020; 18():3947-3949. PubMed ID: 33312454
[TBL] [Abstract][Full Text] [Related]
5. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
Shahbazi B; Mafakher L; Teimoori-Toolabi L
J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
[TBL] [Abstract][Full Text] [Related]
6. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
7. Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor.
Ahsan T; Sajib AA
Biochem Biophys Rep; 2021 Jul; 26():100982. PubMed ID: 33817352
[TBL] [Abstract][Full Text] [Related]
8.
Br B; Damle H; Ganju S; Damle L
F1000Res; 2020; 9():663. PubMed ID: 32765844
[No Abstract] [Full Text] [Related]
9. Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells.
Thuy PX; Bao TDD; Moon EY
Biomed Pharmacother; 2022 Jun; 150():113021. PubMed ID: 35658221
[TBL] [Abstract][Full Text] [Related]
10.
Ayyamperumal S; Jade D; Tallapaneni V; Chandrasekar MJN; Nanjan MJ
J Biomol Struct Dyn; 2022; 40(21):11383-11394. PubMed ID: 34455932
[TBL] [Abstract][Full Text] [Related]
11. In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2.
Chakraborty R; Bhattacharje G; Baral J; Manna B; Mullick J; Mathapati BS; Abraham P; J M; Hasija Y; Ghosh A; Das AK
Comput Biol Med; 2022 Aug; 147():105788. PubMed ID: 35809412
[TBL] [Abstract][Full Text] [Related]
12. The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.
Ahmad I; Pawara R; Surana S; Patel H
Top Curr Chem (Cham); 2021 Oct; 379(6):40. PubMed ID: 34623536
[TBL] [Abstract][Full Text] [Related]
13. Underlying Mechanisms and Candidate Drugs for COVID-19 Based on the Connectivity Map Database.
Li Z; Yang L
Front Genet; 2020; 11():558557. PubMed ID: 33193639
[TBL] [Abstract][Full Text] [Related]
14. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches.
Kalhor H; Sadeghi S; Abolhasani H; Kalhor R; Rahimi H
J Biomol Struct Dyn; 2022 Feb; 40(3):1299-1315. PubMed ID: 32969333
[TBL] [Abstract][Full Text] [Related]
15. Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach.
Loganathan T; Ramachandran S; Shankaran P; Nagarajan D; Mohan S S
PeerJ; 2020; 8():e9357. PubMed ID: 32566414
[TBL] [Abstract][Full Text] [Related]
16. Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection.
Goyal RK; Majeed J; Tonk R; Dhobi M; Patel B; Sharma K; Apparsundaram S
Rev Cardiovasc Med; 2020 Sep; 21(3):365-384. PubMed ID: 33070542
[TBL] [Abstract][Full Text] [Related]
17. In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex.
Buitrón-González I; Aguilera-Durán G; Romo-Mancillas A
Results Chem; 2021 Jan; 3():100094. PubMed ID: 33520633
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
[TBL] [Abstract][Full Text] [Related]
19. In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data.
Das S; Camphausen K; Shankavaram U
Res Sq; 2020 Jun; ():. PubMed ID: 32702730
[TBL] [Abstract][Full Text] [Related]
20. Electronic Cigarette Aerosol Is Cytotoxic and Increases ACE2 Expression on Human Airway Epithelial Cells: Implications for SARS-CoV-2 (COVID-19).
McAlinden KD; Lu W; Ferdowsi PV; Myers S; Markos J; Larby J; Chia C; Weber HC; Haug G; Eapen MS; Sohal SS
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33802256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
